PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
148.49
P/E over 25 - Premium pricing. John Neff would question if growth can possibly justify this multiple. Examine all growth metrics carefully.
No Data
No Data available this quarter, please select a different quarter.
-218.96
Negative P/B (negative equity) is a classic Benjamin Graham red flag. While possibly indicating distress opportunity, verify Debt-to-Equity and examine asset quality carefully.
530.93
P/FCF above 30 - Expensive zone. Benjamin Graham would question if any business can justify such a premium to free cash flow.
530.93
P/OCF above 25 - Expensive zone. Benjamin Graham would question if any business deserves such a premium to operating cash flow.
-218.96
Negative fair value estimate is a serious red flag. Benjamin Graham would demand extraordinary due diligence. Verify all valuation inputs and assumptions.
0.17%
Earnings yield below 3% - Danger zone. Philip Fisher would require extraordinary growth evidence. Examine all growth and quality metrics.
0.19%
FCF yield below 3% - Danger zone. Philip Fisher would require extraordinary growth evidence. Examine all capital allocation metrics.